Recently, Beimei pharmaceutical co., Ltd (hereinafter referred to as the “Beimei”) and Aosaikang Pharmaceutical Co., Ltd (hereinafter referred to as the “Aosaikang”) have made a cooperative promotion authorization agreement on Esomeprazole magnesium delayed release oral suspension (hereinafter referred to as the "Product") in the specified regions and provinces across the ...

Recently, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as Beimei Pharm) and Jiangsu Aosaikang Pharmaceutical Co., Ltd. (hereinafter referred to as ASK Pharm) announced the strategic cooperation. Both parties will integrate the superior resources to jointly promote innovation and research and development of pediatric prescription drugs and solve unmet clinical needs in China, with a view to initiating in-depth cooperation in R&D transformation, manufacturing, sales promotion and equity cooperation.

On June 23, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Italy NTC S.r.l. (hereinafter referred to as "NTC") entered into an exclusive License and Supply Agreement for the collaboration of three EU approved Class II medical device (hereinafter referred to as "Products") in China Mainland. Beimei acquire exclusive right to register and commercialize the Products in China Mainland. The Products are oral care products, suitable for children’s use, in two different dosage forms- spray and gel as topical treatment of the oral mucosa suffering from recurrent canker sores.

From May 7, 2022 to May 8, 2022, all the members of Beimei went to Dapeng, a beautiful seaside town in Shenzhen, to carry out the team building activity, aiming to promote team communication, enhance team collaboration and team cohesion, to build an excellent team of unity, cooperation and enterprising.

Beimei Pharma’sseries B/ B+ financing roundFollowing the completion of the Series A round financing in January 2021, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharma") has recently completed the Series B and B+ financing. Led by Efung Investment Management, followed by Acer Capital, Lianrun Oriental, Hainan Jinbei and other ...

Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") has officially received the acceptance letter issued by the Drug Evaluation Center of the National Medical Products Administration.The sevelamercarbonate powder for oral suspension, which isimportedby Beimei Pharmaceutical,its application was accepted.In March 2022, Beimei ...

On April 1, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Netherlands Synthon B.V. (hereinafter referred to as " Synthon ") reached an exclusive license and supply agreement of a pharmaceutical product for the treatment of hyperphosphatemia (hereinafter referred to as "the product"). Under the te...

The soft wind in early spring brings the most beautiful goddess Festival. On the morning of March 8, President Wu shared with all the fairies of the company how professional women balance work and life.To be a better self, not only shine today!Wish all female friends a happy holiday, healthy and beautiful!

On February 24, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Dr. Reddy'slaboratory Ltd. (hereinafter referred to as "Dr. Reddy's") reached an exclusive license and supply agreement of a pharmaceutical product for the treatment of otic infection (hereinafter referred to as "the product"). ...